UNSPSC 51283514: Nafcillin sodium anhydrous

This classification denotes a beta-lactam antibiotic with the molecular formula C21H21N2O5S.Na, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier SY07234TTS, chemically known as sodium 6-(2-ethoxy-1-naphthamido)penicillanate, but more generally known as nafcillin sodium anhydrous, which bears US NIH Compound Identifier 64712. European Medicines Agency schedules nafcillin sodium anhydrous or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09118MIG.

Most nations, for tariff purposes, schedule nafcillin sodium anhydrous under HS 29411090. Nafcillin sodium anhydrous bears US NLM identifiers UMLS ID C2698426 and NCI Concept Code C76224. SMILES: CCOC1CCC2CCCCC2C1C(=O)N[C@H]3[C@@H]4N(C3=O)[C@H](C(S4)(C)C)C(=O)[O-].[NA+].

UNSPSC 51283514 Nafcillin sodium anhydrous is a Commodity code that nominally names a specific antibiotic pharmaceutical, but recent state and local opportunities tagged under it show little direct procurement activity for this substance. The most recent solicitations are miscoded or tangentially related: Seminole County, Florida solicited naloxone and drug deactivation systems through IFB 60459723LAS (due July 26, 2023); the City of Tampa issued IFB 26P00145 for medical and first aid supplies to the Fire Department Rescue Division (due March 13, 2026); the Texas Health and Human Services Commission posted RFI HHS0017013 for direct-to-manufacturer prescription capabilities (due April 3, 2026); and the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) issued RFP S1070000015802 for generic multi-source pharmaceuticals and OTC products (due March 26, 2026). None of these opportunities explicitly specify nafcillin sodium anhydrous as a line item or product requirement. The issuing bodies span county health departments, municipal fire services, state health agencies, and cooperative purchasing organizations, but the code shows limited recent activity that directly matches pharmaceutical manufacturing or wholesale distribution of this particular antibiotic.

Geographic activity appears scattered across Florida, Texas, Minnesota, and Oregon (through MMCAP participation), but the nafcillin code itself does not appear to drive consolidated procurement volume in any single jurisdiction or region. The miscoding or tangential tagging suggests that state and local buyers may not be using this Commodity code reliably for anti-infective pharmaceutical procurement. Business developers should verify that opportunities tagged under this code align with their product scope before committing resources to pursuit; the recent record does not establish consistent demand signal or a predictable buyer cohort for nafcillin sodium anhydrous specifically.